Luminex

DiaSorin swallows Luminex for $1.8B

Italian laboratory diagnostics producer DiaSorin announced a deal Sunday to buy Texas-based biological test maker Luminex for $1.8 billion.

The deal—funded through a mix of cash and external financing—will broaden DiaSorin’s presence in the United States and expand its growing diagnostics portfolio with access to Luminex’s “multiplexing technology,” the press release said.

The merger comes just weeks after Roche announced plans to expand its molecular diagnostics portfolio with a…

Mentions:
DiaSorin, Luminex, Roche, GenMark, M&A, diagnostics
Read more
Covid-19 development round-up: September 25, 2020

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Novavax, J&J, Janssen, CNBG, Fujifilm Toyama, SII, AstraZeneca, Petrovax, CanSino, Bharat Biotech, BBIL, Codagenix, Clover Pharmaceuticals, Vector Research Center, COVAX, Gavi, Sanofi, GSK, Moderna, SiO2, ReiThera, Valneva, Endo, Technovalia, BioNet, Mymetrics, Precision Biologics, Inovio, Pfizer, Vir Biotechnology, Fiocruz, BCG, Gilead, Hovione, Ligand, ChemRar, RDIF, Relief Therapeutics, NeuroRx, Lumen Bioscience, OncoImmune, Humanigen, Thermo Fisher, SynAct Pharma, Sorrento Therapeutics, Mylan, Ortho, Luminex, Diomics, NIH, BARDA, FDA
Read more
Subscribe to Luminex